WuXi Biologics breaks ground on CRDMO Center in Singapore
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The facility will manufacture tablets, capsules, and injections for the oncology segment
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Hepatitis B infects over 40 million people in India
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Pharma Solutions operates 10 research and development and/or production sites globally
Subscribe To Our Newsletter & Stay Updated